Merck KGaA, Darmstadt, Germany, acquires Silence Therapeutics for $1.3 billion, Hansoh Pharma and Roche expand their ADC partnership in a deal worth over $15 billion, and an EMA panel backs Lilly’s Foundayo for obesity and type 2 diabetes in Europe.
News|Podcasts|September 6, 2024
Beyond the Birthrate: The Societal Costs of Maternal Mortality
Author(s)Miranda Schmalfuhs
Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Advertisement
Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses:
- The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study
- The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make
- Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health
- How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges
- and more!
Advertisement
Related to this article
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
Is Participation in MFN Voluntary?
3
Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion
4
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
5